PERSONAL INFORMATION

Anton Vladic

Clinical Hospital Sveti Duh, Neurology Clinic, Sveti Duh 64, 10 000 Zagreb, Croatia

+385992019770

avladic1@yahoo.com; avladic@kbsd.hr

Date of birth 13/Aug/1959

Nationality Croatian

Sex Male

WORK EXPERIENCE

1986-1987

Doctor

Clinic of Infectious Diseases Fran Mihaljević and Primary Health Centre “Zagreb Centar” - Intern

1987-1988

Reserch Assistant

School of Medicine, University of Zagreb, Department of Pharamcology

1989-1992

Neurology Resident

Clinical Hospital Sveti Duh, Zagreb, Neurology Clinic

1992-

Neurology Specialist

Clinical Hospital Sveti Duh, Zagreb, Neurology Clinic

EDUCATION AND TRAINING

1979-1985

Medical Doctor

School of Medicine, University of Zagreb

1986-1988

Master of Science

Faculty of Science, University of Zagreb

1989-1992

Neurology Specialist

School of Medicine, University of Zagreb

1995

Neurology Specialist, PhD

School of Medicine, University of Zagreb

2018 Training in Acupuncture (Croatian Acupuncture Association)

PROFESSIONAL SKILLS

Mother tongue: Croatian

Other language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C1/2	C1/2	C1/2	C1/2	C1/2

Levels: A1/2: Basic user - B1/2: Independent user - C1/2 Proficient user
Common European Framework of Reference for Languages

Computer skills
- good command of Microsoft Office™ tools

Driving licence
- B

ADDITIONAL INFORMATION

Memberships

Croatian Society of Pharmacologists since 1988
Croatian Neurological Society since 1992
World Federation of Neurological Societies since 1992
European Federation of Neurological Societies since 2004
European Neurological Society since 2005
European Academy of Neurology since 2015
Croatian Acupuncture Association since 2019

Clinical Trials: From 2001 more than 20 clinical trials in the scope of neurology

GCP Certificate: 2020, NIDA CTN

Publications

1. Vladić A, Oreskovic D, Tambic T, Davila D, Bulat M. Penetration of erythromycin and its derivative DCH3/L (azithromycin) through bloodbrain barrier in cats. *Final Report, Pfizer* 1986.

2. Vladić A, Bulat M. Distribution of ^{3}H-inulin by CSF pulsations and body activity into various compartmen of the CSF. *Iugoslav Physiol Pharmacol Acta* 1988;24 *(suppl 6):489-490.*

3. Strikic N, Vladić A, Jurcic D, Klarica M, Bulat M. Role of active transport in distribution of ^{3}H-benzylpenicillin in the CSF system.*Iugoslav Physiol Pharmacol Acta1988;24(suppl6):437-438.*

4. Bulat M, Vladić A, Strikic N. Active transport restricts distribution of ^{3}H-benzylpenicillin along cerebrospi fluid. *Eur J Pharmacol 1990;183(6):2347.*

5. Bulat M, Vladić A, Oreskovic D, Lupret V. Concentration gradients of 5-hydroxyindoleacetic acid in the cerebrospinal fluid system. In: Bulat M, et al. (eds) *Pharmacological communications* 1993: 48-49.

6. Strikic N, Klarica M, Vladić A, Bulat M. Effect of active transport on distribution and concentration gradie of ^{3}H-benzylpenicillin in the cerebrospinal fluid. *Neurosci letters 1994;169:159-162*

7. Vladić A, Bulat M. Dynamics of distribution of ^{3}H-inulin among various compartments of the cerebrospin fluid in anesthetized dogs. *Period biol 1996; 98(1): 37-40.*

*8.*Vladić A, Orešković D, Strikić N, Jurčić D, Bulat M. Effect of body activity and active transport on concentration gradients of 5-hydroxyindoleacetic acid in the cerebrospinal fluid.*Period biol 1997;99 (4):49 497.*

*9.*Vladić A, Strikić N, Jurčić D, Zmajević M, Klarica M, Bulat M. Homeostatic role of the active transport in elimination of [^{3}H] benzylpenicillin out of the cerebrospinal fluid system. *Life Sciences 2000;67:2375-2385.*

10.Jernej B, Vladić A, Čičin-Šain L, Hranilović D, Banović M, Balija M, Bilić E, Sučić Z, Vukadin S, Grgičević I Platelet Serotonin Measures in Migraine. *Headache 2002;42:588-595.*

11.Vladić A, Horvat G, Vukadin S, Sucic Z, Simaga S. Cerebrospinal fluid and serum protein levels of Tum Necrosis Factor-Alpha (TNF-alpha), Interleukin-6 (IL-6) and Soluble Interleukin-6 Receptor (sIL-6R gp80) multiple sclerosis patients. *Cytokine 2002; 20: 86-89.*

12. Filić V, Vladić A, Štefulj J, Čičin-Šain L, Balija M, Sučić Z, Jernej B. Monoamino oxidases A and B gene polymorphisms in migraine patients. J Neurol Sci 2005; 228:149-153.

13.Vladić A, Budinčević H, Matek P. Utjecaj godišnjih doba na migrenu . Neurologia Croatica 2005; 54 (su 4): 58-60.

14.Vladic A, Klarica M, Bulat M. Dynamics of distribution of 3H-inulin between the cerebrospinal fluid compartments. Brain Res 2009;12 (1248):127-35.

15.Bačić Baronica K, Mlinac K, Ozretić D, Vladić A, Kalanj Bognar S.. Gene polymorphisms of Arylsulfatas A in relapse remitting multiple sclerosis: genotype-phenotype correlation and estimation of disease progression using Multiple Sclerosis Severity Score and MRI findings, 2011, Coll Atropol 35(1):11-16

16. Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Bass AD, Wynn DR, Margolin DH, Lake S Moran S, Palmer J, Smith MS, Compston DA. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol. 2011;10(4):338-48.

Publications

17. Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Skoromets A, Stolyarov I, Bass A, Sullivan H, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA. Alemtuzumab more ctive effecitve than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology. 2012(3);78(14):1069-78.

18. Kes VB, Zavoreo I, Serić V, Solter VV, Cesarik M, Hajnsek S, Pasić MB, Gabelić T, Silvio B, Butković SS, Lusić I, Grbelja LD, Vladić A, Bielen I, Antoncić I, Demarin V. Recommendations for and diagnosis and management of multiple sclerosis..Acta Clin Croat. 2012;51(1):117-35.

19. Klarica M, Miše B, Vladić A, Radoš M, Orešković D."Compensated hyperosmolarity" of cerebrospinal flu and the development of hydrocephalus. Neuroscience. 201317;248:278-89.

20. Daniels GH, Vladic A, Brinar V, Zavalishin I, Valente W, Oyuela P, Palmer J, Margolin DH, Hollenstein J. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis.. J Clin Endocrinol Metab. 2014;;99(1):80-89

21. Bačić Baronica K, Mlinac K, Petlevski R, Ozretić D, Vladić A, Kalanj-Bognar S, Zuntar I. Progression of multiple sclerosis is associated with gender differences in glutathione S-transferase P1 detoxification pathway.. Acta Neurobiol Exp (Wars). 2014;74(3):257-65.

22. De Mercanti S, Rolla S, Cucci A, Bardina V, Cocco E, Vladic A, Soldo-Butkovic S, Habek M, Adamec I, Horakov Annovazzi P, Novelli F, Durelli L, Clerico M. Alemtuzumab long-term immunologic effect: Treg suppressor fun increases up to 24 months. Neurol Neuroimmunol Neuroinflamm. 2016; 21;3(1):194.

23. Rolla S, De Mercanti SF, Bardina V, Horakova D, Habek M, Adamec I, Cocco E, Annovazzi P, Vladic A, Nc F,Durelli L, Clerico M. Lack of CD4+ T cell percent decrease in alemtuzumab-treated multiple sclerosis patients persistent relapses. J Neuroimmunol.2017(15);313:89-91

24. Vlasic S, Tomasovic S, Vladic A. Application of dry needling on spastic muscle. Physiother. Croat 2019;16:61-6

25. Rolla S, De Mercanti SF, Bardina V, Maglione A, Taverna D, Novelli F, Cocco E, Vladic A, Habek M, Adam Annovazzi POL Horakova D, and Clerico M Long-term effects of alemtuzumab on CD4+ lymphocytes in Mu Sclerosis patients: a 72 month follow-up. Frontiers in Immunology 2022:28;13:818325

26. Jagnjić S, Bingulac-Popović J, Đogić V, Vladić A, Štingl Janković K, Kruhonja Galić Z, Hećimović A, Jukić I : H alleles and susceptibility to multiple sclerosis in Croatia. Acta Clin Croat., 2023 (Accepted for publication)